The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 2×
“In the pancreas, GLP-1 acts in a well-coordinated and strictly glucose-dependent manner by increasing insulin secretion from β-cells, while simultaneously decreasing glucagon secretion from α-cells and even increasing somatostatin secretion from δ-cells [9,10,15–17].”
BackgroundNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Research works printed but not linked: 31
- Kahn, 2003, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes, Diabetologia, 46, 3, 10.1007/s00125-002-1009-0 · DOI · Paper page
- Brown, 2004, The burden of treatment failure in type 2 diabetes, Diab Care, 27, 1535, 10.2337/diacare.27.7.1535 · DOI · Paper page
- Virally, 2007, Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives, Diab Metab, 33, 231, 10.1016/j.diabet.2007.07.001 · DOI
- Drucker, 2003, Enhancing incretin action for the treatment of type 2 diabetes, Diab Care, 26, 2929, 10.2337/diacare.26.10.2929 · DOI · Paper page
- Holst, 2007, The physiology of glucagon-like peptide 1, Physiol Rev, 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
- Kim, 2008, The role of incretins in glucose homeostasis and diabetes treatment, Pharmacol Rev, 60, 470, 10.1124/pr.108.000604 · DOI · Paper page
- Vilsbøll, 2001, Reduced postprandial concentrations of intact biologically active glucacon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
- Lugari, 2002, Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes, Horm Metab Res, 34, 150, 10.1055/s-2002-23199 · DOI
- Meier, 2008, Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus, Nat Clin Pract Endocrinol Metab, 4, 606, 10.1038/ncpendmet0946 · DOI
- Ørskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, 43, 535, 10.2337/diabetes.43.4.535 · DOI
- Ørskov, 1988, Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach, Endocrinology, 123, 2009, 10.1210/endo-123-4-2009 · DOI · Paper page
- Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
- Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas, Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
- Bulotta, 2002, Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1, J Mol Endocrinol, 29, 347, 10.1677/jme.0.0290347 · DOI
- Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas, Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- Buteau, 2008, GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival, Diab Metab, 34, 73, 10.1016/S1262-3636(08)73398-6 · DOI
- Xu, 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
- Saraceni, 2007, Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function, Drugs R D, 8, 145, 10.2165/00126839-200708030-00002 · DOI
- Mannucci, 2008, Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk, Nutr Metab Cardiovasc Dis, 18, 639, 10.1016/j.numecd.2008.08.002 · DOI
- Pi-Sunyer, 2005, Weight loss in type 2 diabetic patients, Diab Care, 28, 1526, 10.2337/diacare.28.6.1526 · DOI
- Vanhorebeek, 2007, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J, 28, 88
- Deacon, 1995, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects, Diabetes, 44, 1126, 10.2337/diabetes.44.9.1126 · DOI · Paper page
- Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, 981
- Thorkildsen, 2003, Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice, J Pharmacol Exp Ther, 307, 490, 10.1124/jpet.103.051987 · DOI
- Nielsen, 2004, Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regul Pept, 117, 77, 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- Tews, 2008, Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues, Horm Metab Res, 40, 172, 10.1055/s-2008-1042426 · DOI
- Haschke, 2006, The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats — an isolated perfused pancreas study [Abstract], Diabetologia, 49, 400
- Werner, 2008, The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves β-cell function in human pancreatic islets [Abstract], Diabetes, 57, 3
- Werner, 2006, Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia [Abstract], Diabetologia, 49, 398
- Werner, 2007, The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia [Abstract], Diabetes, 56, 129
- Moore, 2007, Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog [Abstract], Diabetologia, 50, S242
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Metadata
- Authors
- Werner, U., Haschke, G., Herling, A. W., & Kramer, W.
- Venue
- Regulatory Peptides
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 164
- Issue
- 2-3
- Pages
- 58-64
- ISSN
- 0167-0115 (ISSN-L)
- OpenAlex
- W2095774646
- Cited by
- 173
- References
- 13
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.regpep.2010.05.008
- The paper
- Werner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010). Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides. https://doi.org/10.1016/j.regpep.2010.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.